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Cell-based screening can facilitate the rapid identification of compounds inducing complex cellular pheno-
types. Advancing a compound toward the clinic, however, generally requires the identification of precise
mechanisms of action. We previously found that epidermal growth factor receptor (EGFR) inhibitors induce
acute myeloid leukemia (AML) differentiation via a non-EGFR mechanism. In this report, we integrated pro-
teomic and RNAi-based strategies to identify their off-target, anti-AML mechanism. These orthogonal
approaches identified Syk as a target in AML. Genetic and pharmacological inactivation of Syk with a drug
in clinical trial for other indications promoted differentiation of AML cells and attenuated leukemia growth
in vivo. These results demonstrate the power of integrating diverse chemical, proteomic, and genomic
screening approaches to identify therapeutic strategies for cancer.INTRODUCTION
We previously discovered that epidermal growth factor receptor
(EGFR) inhibitors induce acute myeloid leukemia (AML) differen-
tiation and inhibit cell viability with case reports of clinical
responses, including two complete remissions (Boehrer et al.,
2008; Chan and Pilichowska, 2007; Pitini et al., 2008; Stegmaier
et al., 2004, 2005). However, the mechanism by which these
molecules induce phenotypic alterations in AML has remained
a mystery because EGFR is not expressed in AML (Lindhagen
et al., 2008; Stegmaier et al., 2005). This specific example
speaks to a more general problem encountered in cell-based,
phenotypic screening. Whereas these screens are quite power-
ful in their ability to identify compounds that modulate complex
biological states, the identification of the direct binding targetof, or cellular pathway modulated by, a discovered chemical
hit can be a serious limitation.
Target identification is critical for the optimization of drug
specificity and potency, the minimization of off-target effects,
and the monitoring of pharmacodynamic studies in clinical
testing. Accordingly, in the absence of a known target, transla-
tion of a compound to clinical trial or optimal use of a compound
with demonstrated efficacy can be stymied, even for Food and
Drug Administration (FDA)-approved drugs. Indeed, there are
many compounds for which the mechanism of action is
unknown, even when clinical efficacy has been demonstrated.
For example, the thalidomide derivative lenalidomide has been
approved by the FDA to treat patients with low or interme-
diate-1 risk myelodysplastic syndrome (MDS) associated with
a deletion 5q cytogenetic abnormality (List et al., 2006).SIGNIFICANCE
Long-term survival for patients with AML remains poor despite dose-intensive chemotherapy regimens. The identification of
pharmacologically tractable targets offers an alternative treatment strategy. We build upon our prior observation that
multiple EGFR inhibitors possess anti-AML activity via a non-EGFR mechanism. We develop a strategy to identify their
off-target activity, integrating proteomic andRNAi-based screening approaches.We identify the kinase Syk as a therapeutic
target in AML and demonstrate that a Syk inhibitor has activity in AML cell lines, primary patient blasts, and in vivo AML
models. With Syk inhibitors already in Phase II trials, these studies can be immediately translated to the clinic and demon-
strate the feasibility of a paradigm for target identification in cell-based screens.Cancer Cell 16, 281–294, October 6, 2009 ª2009 Elsevier Inc. 281
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Dual Approaches Identify Syk as an AML TargetHowever, the majority of patients with MDS lack the 5q deletion,
and, of these patients, a minority respond to lenalidomide (List
et al., 2005). Similarly, sorafenib, initially developed as a RAF
inhibitor, has been approved for patients with advanced renal
cell carcinoma (RCC) in which the relevant target is likely to be
a non-RAF tyrosine kinase (Escudier et al., 2007; Ratain et al.,
2006). Further optimization in the treatment of RCC ideally would
be directed at the relevant target. Because the precise mecha-
nism of action of these drugs is not clear, it has been difficult
to identify a priori which patients will benefit from the drug. Simi-
larly, in the absence of target knowledge, our understanding of
the development of resistant disease is limited at best.
Although target identification has been a significant roadblock
to cell-based screening, this problem now warrants revisiting.
With advances such as the application of high-throughput short
hairpin RNA (shRNA) screening to mammalian systems and
emerging abilities to evaluate the phosphorylated tyrosine ki-
nome, interdisciplinary solutions to this challenge are now
feasible. We decided to undertake this challenge of target iden-
tification by using integrative orthogonal proteomic and genetic
approaches. We explored this strategy in the context of the
gene expression-based screen that identified gefitinib as an
inducer of AML differentiation (Stegmaier et al., 2004, 2005).
As in the case of phenotype-based screening, expression-based
screening faces the challenge of identifying the protein target of
confirmed compound hits. Here, we integrated immunoaffinity
profiling of tyrosine phosphorylation by mass spectrometry
and RNAi-based signature screening to identify candidate gefiti-
nib targets and validated one of these kinases as a target for AML
therapy.
RESULTS
Proteomic and Genetic Approaches Identify Syk
as a Candidate Gefitinib Target
Because multiple EGFR inhibitors induce the AML differentiation
phenotype, we hypothesized that a shared off-target kinase was
the target in AML differentiation. In order to identify candidate
targets, we integrated peptide immunoprecipitation (IP)-HPLC-
mass spectrometry and RNAi-based signature screening.
Specifically, we employed a proteomics approach that involved
IP with a cocktail of three phosphotyrosine antibodies after enzy-
matic digestion to enrich for phosphotyrosine peptides (Fig-
ure S1 available online) (Rush et al., 2005). We treated the AML
cell line HL-60 with gefitinib or vehicle for 10 min and then iden-
tified peptide phosphorylation sites that were lost after gefitinib
treatment by LC-MS/MS (Figure 1A; Table S1). Syk was identi-
fied as one of the few tyrosine kinases that exhibited loss of
phosphorylation posttreatment. Syk is a nonreceptor tyrosine
kinase that was previously shown to play an important role in
normal B cell differentiation and hematopoietic signaling and
has been implicated in hematological malignancies such as
MDS and lymphoma (Chen et al., 2008; Cheng et al., 1995;
Chu et al., 1998; Feldman et al., 2008; Kanie et al., 2004; Kuno
et al., 2001; Rinaldi et al., 2006; Sada et al., 2001; Turner et al.,
1995; Young et al., 2008). Two other direct targets of Syk kinase
activity, the adaptor protein Vav1 and the ubiquitin ligase Cbl,
were also differentially phosphorylated (Deckert et al., 1996;
Lupher et al., 1998).282 Cancer Cell 16, 281–294, October 6, 2009 ª2009 Elsevier Inc.In order to increase our confidence in hits identified by this
proteomics screen, we performed an orthogonal shRNA screen
with a lentivirally delivered shRNA library targeting the human
kinome (Moffat et al., 2006). We screened 5036 shRNAs for
those that induced a complex 19-gene signature of myeloid
differentiation (Table S2). Gene expression was measured by
the previously described approach: Gene Expression-based
High-throughput Screening (GE-HTS) (Stegmaier et al., 2004).
GE-HTS is based on the premise that gene expression signa-
tures can be used for high-throughput screening. GE-HTS
overcomes some of the challenges inherent in traditional
target- and phenotype-based screening in that it is generic,
does not require unique assay customization, and does not
depend on a priori target knowledge. In brief, mRNAs are
captured on 384-well plates coated in oligo-dT and are reverse
transcribed to create cDNA. Then, ligation-mediated amplifica-
tion (LMA) is performed for marker-gene amplification with
universal primers (one set biotinylated). Molecular barcodes
are incorporated into the flanking regions of each amplicon
and are detected by fluorescent beads, each coupled to
a capture oligonucleotide complementary to one of the barco-
des. The use of beads of different colors (each corresponding
to a different barcode capture probe) facilitates quantitation
of the LMA products by dual color flow cytometry. Bead color
denotes the signature transcript identity, and the phycoerythrin
intensity denotes the transcript’s abundance (Peck et al., 2006).
In this integrative approach to target identification, we com-
bined high-throughput RNAi-based screening with high-
complexity signature-based readouts. In the primary RNAi
screen, the total hit rate was 2% for shRNAs scoring across
all scoring metrics. One of these top-scoring shRNAs targeted
SYK (Figure 1B). This shRNA suppressed SYK to the most
significant degree of the five SYK-directed shRNAs included
in the screen.
SYK-Directed RNAi Induces Myeloid Differentiation
in AML Cell Lines
In a secondary screen performed in two AML cell lines, HL-60
and U937, we tested a collection of additional shRNAs designed
to target the top-scoring candidate kinases with an expanded
32-gene myeloid differentiation signature detected by the
GE-HTS assay (Table S3). Multiple shRNAs specific for SYK
scored in both cell lines. We next confirmed that the shRNAs
that triggered the 32-gene differentiation signature indeed
suppress SYK expression (Figures 2A and 2B; Figure S2). These
shRNAs also induce morphological evidence of differentiation,
including nuclear condensation and cytoplasmic ruffling (Fig-
ure 2C), and expression of the mature myeloid cell surface
proteins CD11b and CD14 (Figure 2D; Figure S3A). Expression
of shRNAs that induced the greatest degree of gene suppression
generally resulted in the most striking phenotypic changes.
Taken together, these results suggest that loss of Syk in the
HL-60 and U937 cell lines induces evidence of AML differentia-
tion by multiple measurements.
Pharmacological Inhibition of Syk Induces Myeloid
Differentiation in AML Cell Lines
If Syk plays a role in counteracting differentiation in AML cells,
specifically designed pharmacological Syk inhibitors should
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Figure 1. Proteomic and RNAi-Based Approaches Identify Syk as a Target for AML Differentiation
(A) Peptide-IP/LC-MS/MS was used to identify proteins dephosphorylated upon gefitinib treatment. HL-60 cells were treated with vehicle (DMSO) or gefitinib at
10 mM for 10 min. Phosphotyrosine peptides were identified in Syk, Cbl, and Vav1, which were dephosphorylated with gefitinib. The LC-MS/MS extracted ion
currents (XIC) for all identified pTyr peptide precursor ions belonging to an individual protein were summed and used to calculate differential expression ratios
in DMSO- and gefitinib-treated cells. The specific phosphopeptides and pTyr sites observed are shown in Table S1. CPY01,2,3,5 are control pTyr peptides spiked
into each sample at the same concentration. Positive ratios indicate higher expression for DMSO treatment; negative ratios indicate higher expression for gefitinib
treatment. Ratios of 13 and 13 indicate that phosphopeptides for a protein were only detected in one of the treatments.
(B) High-throughput RNAi Screen Performance. Five scoring methods were used for identifying hairpins inducing a myeloid differentiation signature (Summed
Score, Weighted Summed Score, Naive Bayes, K-Nearest Neighbor, and Support Vector Machine). The majority of shRNAs did not score by any method.
The SYK-specific shRNA (Syk_1) scored in all methods.exhibit prodifferentiation activity. To address this hypothesis, we
chose to focus on the potent Syk inhibitor already in clinical
development, R406, an ATP-competitive pyrimidinediamine
with less potency reported for FLT-3, c-Kit, and Lck (Braselmann
et al., 2006; Weinblatt et al., 2008). First, we confirmed that treat-
ment with either R406 or gefitinib resulted in inhibition of Syk
phosphorylation at Y525/526, the kinase activation site (Fig-
ure 3A). As we found when we suppressed SYK expression
with shRNAs, pharmacological inhibition of Syk induced differ-entiation in HL-60 and U937 cells, as measured by multiple
assays: a 32-gene differentiation signature (Figure 3B); morpho-
logical changes, including nuclear condensation and cyto-
plasmic ruffling (Figure 3C); mature cell surface proteins CD11b
and CD14 (Figure 3D; Figure S3B); and nitro-blue tetrazolium
reduction (Figure 3E), a functional assay of myeloid maturation
measuring superoxide anion production. Taken together, these
genetic and pharmacologic studies implicate Syk as a negative
regulator of differentiation in AML.Cancer Cell 16, 281–294, October 6, 2009 ª2009 Elsevier Inc. 283
Cancer Cell
Dual Approaches Identify Syk as an AML TargetSyk Inhibition Affects a Diverse Set of AML Cell Lines
To determine whether Syk inhibition has broad applicability in
AML, we extended testing to additional AML cell lines, evaluating
effects of pharmacologic and genetic inhibition on growth and
differentiation. When we tested doses up to 10 mM, we found
that all of the AML cell lines tested, except for THP-1, exhibited
decreased viability (Table S4). We hypothesized that Syk would
be differentially phosphorylated across these AML samples, and
that phosphorylation status would predict response to Syk inhi-
bition. Consistent with this notion, the two cell lines with the
greatest degree of Y525/526 phosphorylation, MOLM-14 and
KG-1, were among the most sensitive to the effects of pharma-
cological inhibition of Syk on viability, apoptosis, and colony
formation in methylcellulose (Figures 4A and 4B; Figure S4). In
contrast, R406 had minimal effects on apoptosis in HL-60 cells
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Figure 2. SYK-Directed shRNA Induces Differ-
entiation in AML Cell Lines
(A) Knockdown performance of shRNAs targeting SYK
in HL-60 and U937 cell lines. Transcript levels were
measured at 5 days postinfection with real-time PCR
and are reported for each hairpin (Syk_1, Syk_7, and
Syk_10) relative to the transcript level of a luciferase
shRNA control (Luc). Error bars depict mean ± stan-
dard deviation (SD) across three replicates.
(B) HL-60 and U937 cells were infected with shRNAs
targeting SYK and luciferase (Luc), and differentiation
was evaluated 7 days postinfection. A 32-gene differ-
entiation signature was quantified by the LMA/bead-
based approach, and a weighted summed score
(differentiation score) was calculated for all genes.
Error bars denote mean ± SD of 16 replicates. The
two SYK-specific shRNAs that induced the greatest
degree of gene suppression also induced the highest
differentiation score.
(C) May Grunwald Giemsa staining of HL-60 and U937
cells at 10 and 12 days postinfection, respectively,
with shRNAs targeting SYK demonstrates cellular dif-
ferentiation when compared to a luciferase shRNA
control. Images were acquired with an Olympus
BX41 microscope, 10003 magnification under oil,
and Qcapture software. The scale bar represents
25 mm.
(D) FACS analysis was performed with FITC- and PE-
labeled antibodies for CD11b and CD14, respectively.
At six days postinfection with shRNAs targeting SYK,
HL-60 cells were positive for single-stained CD11b
and CD14 and double staining compared to a lucif-
erase control.
until a dose of 6 mM (data not shown).
However, some AML cell lines that exhibited
Y525/526 phosphorylation, such as THP-1,
were relatively insensitive to R406, whereas
Kasumi-1 with lower levels of p-Syk were
quite sensitive, suggesting that at least
in vitro there are factors other than the
degree of Syk phosphorylation that modify
response to R406.
We next evaluated the genetic inhibition of
Syk in MOLM-14 and KG-1 cells. The intro-
duction of SYK-specific shRNA dramatically
inhibited the proliferation of these cells (Figure 4C). Ectopic
expression of a TEL-Syk cDNA immune to the shRNA rescued
the phenotypic alteration, suggesting that the effects of the
shRNA were on-target for Syk (Figure 4D). Although both pertur-
bagens induce differentiation in KG-1 cells, as measured by
morphological and gene expression changes that precede apo-
ptosis (Figures 4E and 4F; Figure S5), their predominant effects
in MOLM-14 cells were on reduced cell viability. However, the
subtle effects of the shRNA on differentiation were also rescued
with the expression of TEL-Syk. (Figures S6 and S7). These
results suggest that the effects of Syk inhibition on differentiation
and apoptosis can be uncoupled. Indeed, this uncoupling was
previously demonstrated for the EGFR inhibitor erlotinib in
AML (Boehrer et al., 2008). Several lines of evidence support
the conclusion that the primary consequence of R406 is due to284 Cancer Cell 16, 281–294, October 6, 2009 ª2009 Elsevier Inc.
Cancer Cell
Dual Approaches Identify Syk as an AML Targetits effects on Syk rather than an off-target kinase of R406.
Specifically, we found that SYK-specific shRNAs recapitulate
the effects of R406. Second, there is a tight correlation between
loss of Syk phosphorylation with R406 at Y525/526 and the
differentiation score (Figure S8). Moreover, many of the samples
that we used harbor wild-type FLT-3, and FLT-3 wild-type cell
lines did not respond to a FLT-3 inhibitor (Figure S9).
Pharmacological Inhibition of Syk Has In Vivo Activity
in an Orthotopic AML Cell Line and Syngeneic Mouse
Models of AML
Although evaluation of human cell lines in vitro is invaluable in the
preclinical testing of potential antileukemia compounds, the ex
vivo environment cannot fully recapitulate the bone marrow
niche. Thus, in vivo studies are critical. Because KG-1 cells
had the most dramatic level of Syk phosphorylation, we focused
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Figure 3. R406 Induces Differentiation
in AML Cell Lines
(A) Immunoblot of HL-60 cells treated with vehicle,
gefitinib, or R406 for 1 hr. Lysates were immuno-
precipitated with anti-Syk antibody and blotted
with antibody to p-Syk (Y525/526). Treatment
with gefitinib and R406 dephosphorylates Syk at
Y525/526. Total Syk was evaluated for a loading
control.
(B) HL-60 and U937 cells were treated for 3 days
with R406 and DMSO, and a weighted summed
score (differentiation score) was determined. Error
bars denote the mean ± SD of 16 replicates.
A dose response was seen in both cell lines.
High-dose DMSO is known to induce differentia-
tion in HL-60; however, the Differentiation Score
is higher for each corresponding dose of R406.
(C) May Grunwald Giemsa staining of HL-60 and
U937 cells treated for 3 days with DMSO or
R406. R406 induces myeloid maturation in both
cell lines, as characterized by nuclear con-
densation and cytoplasmic ruffling. Images were
acquired with an Olympus BX41 microscope,
10003magnification under oil, and Qcapture soft-
ware. The scale bar represents 25 mm.
(D) FACS analysis was performed with FITC- and
PE-labeled antibodies for CD11b and CD14,
respectively. HL-60 cells were treated for 3 days
with vehicle or R406. R406 induced both CD11b-
and CD14-stained double-positive cells and
single-stained positive CD11b, consistent with
myeloid maturation.
(E) HL-60 cells were treated in triplicate for 3 days
with vehicle, ATRA, or R406. The percentage of
NBT-positive cells and mean ± SD are shown.
Both ATRA and R406 reduced NBT, consistent
with the functional maturity of HL-60 cells.
our attention on this cell line. First, we
evaluated colony formation in methylcel-
lulose. Both chemical and genetic inhibi-
tion of Syk abrogated colony-forming
potential in KG-1 cells (Figure 5A; Fig-
ure S4). Next, we used an orthotopic
xenograft model in which KG-1 cells
were labeled with luciferase and propa-
gated in NOD-SCID IL2Rgnull (NOG) xenografts. Eight days of
treatment with R788, the prodrug of R406, resulted in signifi-
cantly decreased leukemia burden (p < 0.05) and spleen weight
(p < 0.001) compared to control-treated animals (Figure 5B;
Figure S10). Moreover, to confirm these findings made in human
cancer cell lines in primary murine AML, we extended in vivo
testing of Syk inhibition to a syngeneic mouse model of MLL-
AF9 AML (Stubbs et al., 2008). Again, 8 days of treatment with
R788 resulted in significantly decreased leukemia burden (p <
0.005) and spleen weight (p < 0.01) compared to control-treated
animals (Figure 5C; Figure S11).
Syk Is Constitutively Active in Primary AML Blasts
Cell lines have been a critical tool for cancer discovery, but
extrapolation of response to primary disease can be problematic
secondary to selection for, or acquisition of, additional geneticCancer Cell 16, 281–294, October 6, 2009 ª2009 Elsevier Inc. 285
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Dual Approaches Identify Syk as an AML Targethits ex vivo. Although studies in primary patient AML blasts are
notoriously challenging, they are critical in the validation of ther-
apeutic targets and response to small-molecule inhibitors. We
first determined whether Syk is expressed in primary AML blasts.
Syk mRNA had previously been reported to be widely expressed
in AML (Tomasson et al., 2008), and we identified Syk protein in
over 90% of primary AML samples evaluated by immunoblotting
(Figure S12). Moreover, using phosphorylation at Y525/526 as
a marker of Syk activation, we identified Syk phosphorylation
that was abrogated by R406 in an independent collection of
primary patient AML blasts for which we obtained adequate cells
(Figure 6A). These observations suggested that Syk was not only
expressed but constitutively active in primary AML blasts.
The Majority of Primary AML Blasts Respond to Syk
Inhibition In Vitro
We next asked whether Syk inhibition would induce differentia-
tion and/or inhibit cell viability in primary AML blasts in vitro. First,
we tested the in vitro activity of R406 in primary cells from
a patient with acute promyelocytic leukemia (APL), the clinical
AML subtype most responsive to differentiation therapy in vivo.
Syk inhibition induced differentiation, evaluated by changes in
gene expression and morphological appearance with nuclear
condensation and lobulation, comparable to the well-validated
differentiation agent, all-trans retinoic acid (ATRA) (Figure 6B).
We next extended testing to 13 additional AML patient samples
widely representing the French-American-British (FAB) sub-
classes and one chronic myelomonocytic leukemia (CMML)
sample. Twelve of these thirteen AML patient samples re-
sponded with an IC50 (drug concentrations that reduced cell
viability to 50 percent of the vehicle controls) less than 1 mM at
3 days (range of 0.05 to 0.7 mM) (Figure 6C; Table 1). We noted
that one sample from a patient with relapsed M1-AML and
another from a patient with CMML failed to respond at doses
up to 4 mM. R406 induced evidence of differentiation in 6 of 13
evaluable patient samples in addition to the APL sample (Figures
6B and 6C). As in the case of AML cell lines, the effects of R406
on differentiation and viability were sometimes uncoupled.
Treatment response was independent of the FAB subtype.
Pharmacological Inhibition of Sykwith R788HasActivity
in a Primary AML Orthotopic Model and a Therapeutic
Index in AML
There is an ongoing debate about the utility of conventional
mouse models for predicting successful therapies in humans.In response, there has been a shift in the experimental approach
to in vivo animal studies; mouse models with tumors collected
directly from primary human tumors have been developed. In
order to address this issue, we tested R788 in a primary human
AML orthotopic model. A primary patient M4-AML sample
responsive in vitro to R406 (patient 11) was used for generating
a human xenograft in NOG mice by tail vein injection. Seventy
days postinjection, mice developed greater than 40% peripheral
AML blasts, as measured by human specific CD45+ cells from
peripheral blood. Mice were then divided into two cohorts, with
two animals per cohort. One group received R788, the second
a placebo. A NOG control mouse without human AML was
included. Six days posttreatment, tail vein blood was sampled,
and the two treated animals were noted to have a decrement
in human specific CD45+ cells (Figure 7A). At day 7, animals
were sacrificed. Spleen weights were dramatically different
across the groups: control mouse, 0.03 g; placebo-treated,
0.14 g and 0.16 g; and R788-treated, 0.04 g and 0.05 g. Histopa-
thology of the bone marrow and spleen (Figure 7B) revealed
a dramatic decrease in the number of infiltrating AML cells. We
next explored the therapeutic window of R406 by comparing
the effects of R406 on primary AML blast colony formation in
methylcellulose compared to normal CD34+ myeloid progenitor
cells. All six primary AML samples were more sensitive to the
effects of R406 than were the normal CD34 myeloid progenitor
cells, suggesting that there is a therapeutic index for R406 in
AML (Figure 7C).
DISCUSSION
Cure rates for patients with AML have remained poor despite
intensive chemotherapy and stem cell transplantation. For older
adults, long-term survival is dismal, and many older patients are
unable to tolerate standard cytotoxic therapy. Although much
has been learned about the pathogenesis of AML, many of the
potential targets involve abnormalities of transcription factors,
a class of proteins considered ‘‘undruggable’’ with standard
pharmacological methods. Emerging approaches, such as
RNAi-based methods (Vorhies and Nemunaitis, 2009), gene
expression-based methods (Lamb et al., 2006; Stegmaier
et al., 2007), stapled peptide technology (Walensky et al.,
2004), or other peptide-based methods (Polo et al., 2004) may
ultimately enable targeting of this important protein class. Alter-
natively, the identification of more pharmacologically tractable
targets in AML offers a parallel route to therapies for this disease.Figure 4. Syk Inhibition Affects a Diverse Set of AML Cell Lines
(A) Western immunoblot of AML cell lines reveals MOLM-14 and KG-1 cell lines to be highly phosphorylated at the p-Syk (Y525/526) enzymatic site.
(B) MOLM-14 and KG-1 cells were treated with vehicle or R406 for 6 days. Cells were stained with annexin V-FITC and propidium iodine (PI) and evaluated by flow
cytometry. R406 treatment induced increased annexin V-positive cells in a dose-responsive manner, consistent with apoptosis.
(C) MOLM-14 and KG-1 cells were infected with shRNAs targeting SYK and luciferase. After 8 days of infection, cell viability was evaluated at days 0, 3, and 6 with
an ATP-based assay. Genetic loss of Syk resulted in a dramatic decrease in proliferation. Error bars depict mean ± SD across ratios of six replicate measurements
at each time point relative to the six replicate measurements at time zero.
(D) Ectopic expression of TEL-Syk immune to the SYK-directed shRNA Syk_1 in MOLM-14 cells rescues the effects of Syk knockdown on cell viability. Cell
viability was evaluated 4 days after infection at days 0, 3, and 6 with an ATP-based assay. Error bars depict mean ± SD across ratios of eight replicate measure-
ments at each time point relative to the eight replicates at time zero.
(E) May Grunwald Giemsa staining of KG-1 cells at 12 days postinfection with shRNAs targeting SYK versus a luciferase shRNA control demonstrates evidence of
macrophage-like differentiation. Images were acquired with an Olympus BX41 microscope, 10003magnification under oil, and Qcapture software. The scale bar
represents 25 mm.
(F) KG-1 cells were treated with R406 versus DMSO, and the 32-gene differentiation signature was measured at 24 hr. R406 induces a myeloid differentiation
signature, as measured by a weighted summed score (differentiation score). Error bars depict mean ± SD across eight replicates.Cancer Cell 16, 281–294, October 6, 2009 ª2009 Elsevier Inc. 287
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Figure 5. R406 Has In Vivo Activity in AML
(A) The ability of KG-1 to form colonies in methylcellulose with R406 and multiple shRNAs directed against SYK was assessed. Both chemical and genetic inhi-
bition of Syk abrogate colony formation in KG-1. The scale bar represents 1 mm.
(B) KG-1 luciferase-positive xenografts were established in NOG mice. Mice were treated with placebo (n = 4), food impregnated with 5 g R788/kg AIN-76A food
(n = 5), and food impregnated with 8g/kg AIN-76A food (n = 3) for 8 days. Mice treated with R788 had a significant difference in tumor burden compared to those
treated with placebo. Serial in vivo BLI was used to assess disease burden, and data were plotted as the mean ± SEM for each group. One way ANOVA analysis
with Tukey post-test was used to determine the significance of all pairwise comparisons.
(C) A syngeneic, luciferase-positive mouse model of MLL-AF9 AML was established in C57BL/6:TyrC/C mice. Mice were treated with placebo (n = 10) or food
impregnated with 3g R788/kg AIN-76 food (n = 10) for 8 days. Serial in vivo BLI was used to assess disease burden and plotted as mean ± SEM. Statistical signif-
icance was calculated with a Student’s t test.In this work, we build upon the striking observation that
multiple EGFR inhibitors had anti-AML activity via a non-EGFR
mechanism, and we hypothesized that this was via a shared
off-target effect. We integrate cross-disciplinary proteomic and
genetic approaches to meet the difficult challenge of under-
standing the molecular basis for the biological activity of these
EGFR inhibitors in AML. At the intersection of these two
approaches, Syk was identified as a tyrosine kinase target in
AML. Syk is a cytoplasmic tyrosine kinase widely expressed in
hematopoietic cells and critical in B cell differentiation and signal
transduction pathways. Syk is a member of the Syk/ZAP-70
family of nonreceptor kinases and is characterized by two
N-terminal Src homology 2 domains and a C-terminal kinase
domain separated by a flexible linker (Sada et al., 2001). Syk acti-288 Cancer Cell 16, 281–294, October 6, 2009 ª2009 Elsevier Inc.vation has been implicated in a variety of hematopoietic cellular
responses (Chu et al., 1998; Sada et al., 2001; Turner et al.,
2000), and there is a growing literature supporting the role of
Syk in hematological malignancies, particularly the lymphomas
(Chen et al., 2008; Feldman et al., 2008; Rinaldi et al., 2006;
Streubel et al., 2006). Interestingly, we see variable patterns of
p-Syk expression and response to R406 in acute lymphoid
leukemia cell lines (Figure S13; Table S5).
Our demonstration of a role for Syk in the pathogenesis of
myeloid malignancies is supported by the case report of the
fusion of the TEL to the Syk gene in a patient with MDS with
t(9;12)(q22;p12) (Kuno et al., 2001). Importantly, this TEL-Syk
fusion transformed the interleukin-3-dependent murine hemato-
poietic cell line Ba/F3 to growth factor independence (Kanie
Cancer Cell
Dual Approaches Identify Syk as an AML Targetet al., 2004). Syk mRNA transcript has been reported to be
expressed in primary AML blasts (Tomasson et al., 2008), and
its expression correlated with response to treatment with gemtu-
zumab ozogamicin (Balaian and Ball, 2006). In our studies, we
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Figure 6. Primary AML Cells Are Respon-
sive to Syk Inhibition In Vitro
(A) Fresh primary patient AML cells were treated
in vitro with vehicle versus R406, and Syk phos-
phorylation at Y525/526 was assessed by immu-
noblotting. In all four samples, Syk is phosphory-
lated at the kinase activity site, and this
phosphorylation is inhibited by R406.
(B) Primary AML blasts were treated with DMSO,
ATRA, or R406 for 3 days, and the 32-gene differ-
entiation signature was evaluated. Error bars
denote mean ± SD across eight replicates per
condition. R406 induces comparable or greater
levels of differentiation to ATRA. May Grunwald
Giemsa staining of ATRA- and R406-treated
primary AML at 4 days reveals myeloid differentia-
tion with lobulation of nuclei in the APL sample and
macrophage-like differentiation in Patients 12 and
13. Images were acquired with an Olympus BX41
microscope, 10003 magnification under oil, and
Qcapture software. The scale bar represents
25 mm.
(C) Primary patient AML cells were treated in
quadruplicate with R406 in a two-fold dilution
series. At day 3, cell viability was evaluated with
an ATP-based assay. Values for the IC50 are
depicted with error bars denoting the 95% confi-
dence interval for the SEM for the four chemical
replicates relative to the four control replicates.
At day 3, the 32-gene differentiation signature
was measured. Samples are scored as differenti-
ating if there was a 1.5-fold change in the Differen-
tiation Score across at least two doses with p <
0.05 by a one-tailed t test assuming two samples
with unequal variance.
demonstrate that Syk protein is not only
expressed but is also constitutively acti-
vated in nearly all of the samples evalu-
ated. Determining the mechanism of
activation of Syk and its critical down-
stream effectors in AML is under active
investigation.
The screening of libraries enriched for
FDA-approved compounds is an attrac-
tive strategy by which to repurpose drugs
for alternative indications and to more
rapidly test clinically relevant hypotheses
in patients. However, the potency and
selectivity of such drugs are often not
optimal for discovered indications. More-
over, there is the desire to optimize
on-target activity and minimize off-target
side effects. Although EGFR inhibitors
have had anti-AML effects, including
complete responses, these molecules
do not potently inhibit Syk and are often
not well tolerated at doses anticipated to inhibit Syk in vivo.
Therefore, we need to identify more potent and selective Syk
inhibitors for this indication. The Syk inhibitor R788 is the orally
available prodrug of R406. Phase I testing of R788 has beenCancer Cell 16, 281–294, October 6, 2009 ª2009 Elsevier Inc. 289
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state concentrations of 1–3 mM, and trough concentrations of
1 mM (E. Grossbard and Rigel Pharmaceuticals, personal
communication). In phase I testing in patients with rheumatoid
arthritis and heavily pretreated patients with lymphoma, the
drug has been well tolerated, and significant clinical activity
has been demonstrated (Weinblatt et al., 2008; M. Shipp,
personal communication). In our studies, the majority of primary
patient AML samples responded in a clinically achievable dose
range, with an IC50 below the serum trough concentration in hu-
mans. Thus, these observations suggest that inhibition of Syk
can be achieved with doses in use in current clinical trials.
The last decade has seen a marked shift in the approach to
cancer-related small-molecule library screening performed by
the pharmaceutical industry with a transition away from pheno-
type-based screening and a primary focus now on target-based
screening. Although target-based screening has been successful
for known, tractable protein targets, as with any approach, it does
have limitations. The majority of known oncoproteins are not
considered easily druggable, and for many malignancies, driver
events have not yet been identified. In addition, target-based
screening is most commonly performed with ex cellulo assays
and may not fully recapitulate the complexity within a cell. Alterna-
tive screening approaches, such as traditional phenotype-based
and expression-based approaches, create the possibility of
screening in the absence of a priori target knowledge. Moreover,
Table 1. Primary Patient AML Characteristics
Patient Diagnosis Cytogenetic Findings
FLT-3
ITD
FLT-3
D835
Codon
Change
1 M1-AML 89-92, XXXX No No
2 M2-AML 45 XY, -7, inv(3)(q21q26) No No
3 CMML Complex karyotypea N/A N/A
4 M4-AML 46 XY No D835H
5 M4-AML 46 XX No D835E
6 M2-AML 46 XX Yes No
7 M3-AML 47 XX, +8, t(15;17) (q22;q21) Yes No
8 M4-Eo 45 X,-Y[11]/46, XY[9]. Nuc
ish (CBF x2) [100]
No No
9 M1-AML 46 XX No No
10 M-5b-AML 46 XX No D835Y
11 M4-AML 46 XY Yes No
12 AMLb N/A Yes No
13 AMLb 46 XY No No
14 M4-AML 46 XY Yes No
15 AMLb 47 XX, +8 [19]/46, XX [1] Yes No
31 M7-AML 52,XY,+8,+14,+19,+21,+21,
+21c[14]/47,XY,+21c[6]
N/A N/A
N/A, not available.
a 46, XY, t (1;19) (p36;q13), del (2) (p2?3), t (3;15) (p21;q22), add (4) (q35),
-6, der (7) t (7;14) (q36;q11.2), -14, -21 + mar [cp10]/46 XY, del (2) (p2?1),
add (7) (q11.2) [cp4]/46, XY, add (1) (q42), t (1;14) (p12;q11), del (3) (q1?3),
der (7) del (7) (q3?1q3?4) t(3;7) (q13;p22, t(17;21) (q2?1;q22) [2]/46, XY,
nonclonal abnormalities [4].
b FAB not reported.290 Cancer Cell 16, 281–294, October 6, 2009 ª2009 Elsevier Inc.expression-based screening holds promise for modulating
intractable targets and can be systematized as a screening para-
digm. However, the transition from compound discovery to drug
development has been stymied for these cell-based screens by
the challenge of identifying the protein target of the identified
compound. Emerging genomic, genetic, and proteomic ap-
proaches have altered the landscape of target identification for
cancer. Similarly, these approaches can transform the drug
discovery process. Their integration into the compound discovery
phase has already begun. Our work suggests that a cross-disci-
plinary integration of genome-wide expression profiling, proteo-
mics, and high-throughput RNAi-based screening could system-
atize protein target identification for cell-based chemical screens.
Moreover, innovations in synthetic chemistry and proteomics
should further facilitate this process in the future. For example,
diversity-oriented synthesis of small-molecule collections allows
for the incorporation of chemical handles to facilitate efficient,
systematic attachment of affinity resins (Burke et al., 2003). After
affinity capture, the specific protein/compound interactions can
be identified by differential isotopic labeling of amino acids as
recently described (Ong et al., 2009).
In conclusion, we demonstrate that the majority of AML cell
lines and primary blasts, and three in vivo AML models, had
a therapeutic response to Syk inhibition with effects on cell
growth and differentiation. With an orally available, well-tolerated
Syk inhibitor currently in clinical development for other indica-
tions, the results reported here should have immediate relevance
for clinical testing of Syk inhibition in patients with AML. Further-
more, these results demonstrate the feasibility of integrating
shRNA-based screening and phosphoproteomic studies to
identify small molecules and their mechanisms of action.
EXPERIMENTAL PROCEDURES
Cell Culture
Primary patient AML blasts were collected from peripheral blood or bone
marrow aspirate after obtaining patient informed consent under Dana-Farber
Cancer Institute- and the University of Pennsylvania Internal Review Board-
approved protocols. Mononuclear cells were isolated with Ficoll-Paque Plus
(Amersham Biosciences), and red blood cells were lysed. Cryopreserved
human bone marrow CD34+ cells were obtained from Poietics, and use of
these materials is considered exempt as human subjects by the Dana-Farber
Cancer Institute Internal Review Board.
HL-60, U937, Kasumi-1, and KG-1 were purchased from the American Type
Culture Collection. THP-1, MOLM-14, 697, NALM-6, REH, RS4-11, SEMK2,
and SUP-B15 were kindly provided by Dr. Scott Armstrong. DND-41, HPBALL,
KOPTK1, MOLT-4, and PF-382 were all kindly provided by Dr. Jon Aster. All
cell lines and primary patient cells were maintained in RPMI 1640 (Cellgro) sup-
plemented with 1% penicillin-streptomycin and 10% fetal bovine serum
(Sigma-Aldrich) at 37C with 5% CO2.
Chemicals
Gefitinib (WuXi PharmaTech, Shanghai, China) and all-trans retinoic acid
(ATRA) (Sigma-Aldrich) were dissolved in dimethyl sulfoxide (DMSO) and
stored at 20C. R406 (Rigel Pharmaceuticals, Inc., San Francisco, CA) was
resuspended in DMSO and stored at 80C. R788 was also supplied by Rigel
Pharmaceuticals.
Phosphoproteomic Studies
HL-60 cells (13 109) were treated in duplicate with 10 mM gefitinib for 10 min.
On the basis of a protocol described by Rush et al. (2005), protein lysate was
extracted with a urea-containing lysis buffer and protease inhibitor. Upon
reduction of the disulfide bonds and the alkylation of cysteines with
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Figure 7. Primary AML Is Responsive to Syk Inhibition in an Orthotopic Model
(A) A primary AML (patient 11) orthotopic xenograft was established in NOG mice. Six days after initiation of treatment with food containing 5g R788/kg AIN-76
rodent diet, the AML blast percentage, measured by percentage of human specific CD45+ cells in peripheral blood, continued to increase in the placebo-treated
mice but decreased in the R788-treated mice.
(B) Histopathology studies of bone marrow in R788-treated versus placebo-treated animals reveal near resolution of AML infiltration with areas of necrosis and
areas of recovering marrow identified. Hematoxylin and eosin staining of spleen reveals areas of leukemic infiltration and extramedullary hematopoiesis in
placebo-treated mice and near resolution of AML infiltration in the R788-treated animals. Images were acquired with an Olympus BX41 microscope, 10003
magnification under oil, and Qcapture software. The scale bar represents 25 mm.
(C) The ability of normal CD34 myeloid progenitor cells and primary patient AML blasts to form colonies in methylcellulose with R406 was assessed. Colony
formation was assessed in duplicate, and colonies per 4 cm2 were counted and displayed relative to control cells. Error bars depict mean ± SD across four ratios
of dose response to vehicle. Primary patient AML blasts were more sensitive to the effects of R406 than were normal myeloid progenitors.iodoacetamide, the lysate was split into two aliquots and diluted with 20 mM
HEPES to 2 M or 0.5 M urea before digestion with trypsin or chymotrypsin,
respectively. The total peptide mixtures were then desalted by Sep-Pak
cartridge and resuspended in immunoprecipitation (IP) buffer, 50 mM
MOPS/NaOH (pH 7.2), 10 mM Na2PO4, 50 mM NaCl, along with four exoge-
nous pTyr-containing peptides added as controls. IP was performed with
a cocktail of three protein G agarose bead-bound phosphotyrosine antibodies,
pY100 (Cell Signaling), 4G10 (UpState), and pY99 (Santa Cruz Biotechnology),to enrich for phosphotyrosine-containing peptides. Peptides captured by
phosphotyrosine antibodies were eluted under basic solutions and then under
acidic conditions. The IP eluates were analyzed by data-dependent LC/MS/
MS with a ThermoFisher LTQ-Orbitrap instrument. All MS and MS/MS data
were processed with the Spectrum Mill software package, which assigns
peptide identity with a <1% false discovery rate with a target-decoy database
search approach, maps phosphorylation sites, and quantitates with extracted
ion chromatograms of each peptide precursor ion (Table S1).Cancer Cell 16, 281–294, October 6, 2009 ª2009 Elsevier Inc. 291
Cancer Cell
Dual Approaches Identify Syk as an AML TargetDifferentiation Studies
Morphological Evaluation
Changes in cellular morphology were evaluated by May Grunwald Giemsa
staining (Sigma) under light microscopy under oil at 10003 magnification
with an Olympus BX41 microscope and Q-capture software.
Nitro-Blue Tetrazolium Reduction Assay
Nitro-blue tetrazolium (NBT) reduction assays were performed in triplicate.
Compound-treated cells were compared to DMSO-treated controls after 3
days of treatment. Cells were incubated at 37C for 1 hr in a mixture containing
total medium, 0.1% NBT (Sigma), and 1 mg/ml TPA (12-O-tetradecanoylphor-
bol-13-acetate; Sigma). The percentage of blue cells was counted by light
microscopy for at least 200 cells per sample. Drug-treated cells were
compared with DMSO-treated cells with a one-tailed t test analysis assuming
two samples with unequal variance.
Flow Cytometry
Cells were stained with 1:25 CD11b-FITC (Beckman Coulter IM0530U) and 1:25
CD14-PE (Beckman Coulter IM0650U) for 30minand detected by flowcytometry
(Beckman Cytomics FC500). Data were analyzed with the FlowJo software
package (TreeStar).Fluorescencegatingwas set basedonsingle-stainedmouse
Ig k compensation bead fluorescence intensity (BD Biosciences #552843).
Gene Expression Studies
Marker genes for myeloid differentiation were chosen with previously pub-
lished Affymetrix AML-related data sets (Stegmaier et al., 2004). We selected
an initial collection of 19 genes used in the RNAi primary screen and then an
expanded group of 32 genes. (Tables S2 and S3). These genes distinguish
AML from either neutrophil or monocyte with p < 0.05 by t test and distinguish
undifferentiated versus differentiated HL-60 with ATRA, PMA, or VitD with p <
0.05 by t test. The GE-HTS assay was performed as detailed in the Supple-
mental Experimental Procedures. Two primary methods are used to compare
signature gene induction. The Summed Score combines expression ratios
(marker gene/control gene) by summing them with a sign determined by the
expected direction of regulation from gefitinib- or ATRA-treated positive
controls. The Weighted Summed Score combines expression ratios by
summing them with a weight and sign determined by the signal-to-noise ratio
of each expression ratio for the positive control (gefitinib- or ATRA-treated) and
negative control (DMSO-treated) samples.
Viability Assay
Viability experiments were performed with the Promega Cell-Titer Glo ATP-
based assay per the manufacturer’s instructions. Values for IC50 (drug concen-
trations that reduced cell viability to 50 percent of the vehicle controls) were
calculated by interpolating a natural cubic spline fit to the measured viability
data in R (with the spline function).
Apoptosis Studies
AML cell lines were treated in triplicate with DMSO versus R406 for 6 days.
Annexin V FITC/PI staining was performed with the Annexin V:FITC Apoptosis
Detection Kit I (BD PharMingen). Cells were analyzed by flow cytometry with
a FACScan flow cytometer (Becton Dickinson) and CELLQuest analytical
software.
Methylcellulose Colony-Forming Assay
For the RNAi studies, KG-1 and MOLM-14 cells were infected with shRNA
directed against a luciferase control or SYK (three unique constructs). After
48 hr of puromycin selection, cells were recounted by trypan blue exclusion,
and 3 3 104 were plated at 1:10 (vol/vol) in methylcellulose (ClonaCell-TCS
Medium, 03814) with 1% penicillin-streptomycin and appropriate drug treat-
ment. For pharmacological treatment of primary AML, AML cell lines, and
normal CD34 myeloid progenitor studies, cells were treated with R406 or
matched vehicle control for 48 hr in liquid culture. After 48 hr, an equal number
of cells were plated at 1:10 (vol/vol) in MethoCult GF+H4435 methylcellulose
(StemCell Technologies, #04445) with 1% penicillin-streptomycin and appro-
priate drug treatment. All plates were incubated at 37C and 5% CO2, and
colony numbers were counted 8–17 days later.
RNAi Screening
High-throughput screening was performed with the RNAi Platform at the
Broad Institute. HL-60 cells were plated in a 384-well format in 30 ml medium292 Cancer Cell 16, 281–294, October 6, 2009 ª2009 Elsevier Inc.at 15,000 cells/well and incubated overnight at 37C with 5% CO2. Polybrene
(Sigma) was added to a final concentration of 8 mg/ml. The lentivirally delivered
sublibrary of the RNAi Consortium shRNA library (http://www.broad.mit.edu/
rnai/trc/lib) was screened in quadruplicate (Moffat et al., 2006). Virus was
added at 2.5 ml per well, and plates were spun for 30 min at 2250 rpm and
were incubated for 48 hr. Selection was performed on three replicates with
1 mg/ml puromycin (Sigma), and medium was changed on the unselected
control plate. Uninfected controls included cells only (8 wells), 1 mM ATRA
(8 wells), and 25 mM gefitinib (8 wells). Plates were incubated for 72 hr. ATP-
based viability was assessed for one puromycin-treated plate and the unse-
lected plate with Cell-Titer Glo (Promega). GE-HTS was carried out on two
replicates, as previously described, with a 19-gene myeloid differentiation
signature. (see Supplemental Experimental Procedures and Table S2) (Peck
et al., 2006; Stegmaier et al., 2004).
Screen plates were filtered and scaled, and five scoring algorithms were
applied: Summed Score, Weighted Summed Score, Naive Bayes, K-Nearest
Neighbor (KNN), and Support Vector Machine (SVM). An shRNA was consid-
ered a hit if the shRNA was classified as being more like gefitinib-treated
controls than untreated HL-60 controls by all five methods (see Supplemental
Experimental Procedures for details of the analysis). A secondary screen was
performed as described above, with the following exceptions: HL-60 and U937
cells were plated at 15,000 cells/well and 4,500 cells/well, respectively.
shRNAs that scored in the primary screen, as well as additional available
shRNAs developed against the hits, were screened in five replicates. In addi-
tion, an expanded 32-gene myeloid differentiation signature was measured
(Table S3).
Lentiviral Vectors and Infection
Oligonucleotides encoding shRNAs were cloned into pLKO.1 as described
previously (Moffat et al., 2006). Sequences targeted by each SYK shRNA are
listed in Table S6. For large-scale infections, 500,000 293T cells were plated
in 6 cm plates and transfected 24 hr later with 1 mg DNA from lentiviral back-
bone vector and packaging plasmids (pCMVdeltaR8.91 and pMD.G) accord-
ing to FuGENE 6 (Roche) protocol. Medium was changed to RPMI 1640 24 hr
posttransfection, and viral supernatant was harvested and filtered 48 hr post-
transfection. Cells were infected for 2 hr at 37C with 2 ml lentivirus and 8 mg/ml
polybrene (Sigma). Cells were selected 48 hr later with 1 mg/ml puromycin
(Sigma).
For generating the TEL-Syk construct, RT-PCR was used to isolate the
sequences encoding amino acids 1–336 of human ETV6 (TEL) and amino acids
266–635 of human Syk. The assembled cDNA was subcloned in place of
mCherry in the lentiviral plasmid FUW-Luc-mCherry-puro (Kimbrel et al.,
2009) to give the plasmid FUW-Luc-TEL-SYK-puro. VSVG-pseudotyped virus
was produced by cotransfection of 293T cells along with the helper plasmids
delta8.9 and CMV-VSVG. Infection of MOLM-14 was performed as described
above.
Real-Time PCR
Total RNA was isolated with TRIZOL reagent (Invitrogen), cDNA was synthe-
sized with SuperScript III Reverse Transcriptase (Invitrogen) and oligo d(T)16
primers, and cDNA was analyzed in the real-time quantitative PCR reactions
prepared with TaqMan Universal Master Mix (Applied Biosystems). RPL13A
expression was evaluated for each sample as a control for total RNA. Primers
and probes for real-time RT-PCR were obtained from Applied Biosystems
(RPL13A # Hs01926559_g1 and SYK Hs00895374_m1).
Immunoblotting
Cells were lysed in Cell Signaling Lysis Buffer (Cell Signaling) containing
Complete, EDTA-free Protease Inhibitor Cocktail Tablet (Roche Diagnostics)
and PhosSTOP Phosphatase Inhibitor Tablet (Roche Diagnostics), resolved
by gel electrophoresis, and transferred to nitrocellulose membranes (BioRad
Laboratories). Blots were incubated with primary antibodies to p-Syk (Y525/
526) (Cell Signaling, 2711), total Syk (Santa Cruz Biotechnology, SC-1240),
b-Actin (Abcam, ab8227-50), GAPDH (Abcam, ab22556-100), or Vinculin
(Abcam, ab18058), followed by secondary antibodies anti-rabbit-HRP (Amer-
sham #NA9340V) or anti-mouse-HRP (Amersham #NA9310V). Bound anti-
body was detected by chemiluminescence. For IP, 2 mg of each protein in lysis
buffer was incubated with 2 mg/ml anti-Syk antibody (Santa Cruz, SC-1240) for
Cancer Cell
Dual Approaches Identify Syk as an AML Target4 hr at 4C. The immunocomplex was precipitated with 30 ml UltraLink Immo-
bilized Protein A/G beads (Pierce) overnight at 4C. The beads were then
washed twice with cold 13 Cell Signaling Lysis Buffer (Cell Signaling) contain-
ing protease inhibitor, resuspended in 10 ml 43 SDS sample buffer, and boiled
for 5 min. The protein was then separated by gel electrophoresis and trans-
ferred to a nitrocellulose membrane (BioRad Laboratories). Blots were probed
with anti-pSyk (Y525/526) (Cell Signaling #2711) and incubated with anti-
rabbit-HRP (Amersham #NA9340V). Bound antibody was detected by Super-
Signal West Dura Extended Duration Substrate (Pierce).
In Vivo Studies
All animal studies were performed on Dana-Farber Cancer Institute Institu-
tional Animal Care and Use Committee (IACUC)-approved protocols. For
KG-1 xenografts, 3 hr prior to injection, 6-week-old male NOD-SCID IL2Rgnull
mice (NOG, Jackson Laboratory) were sublethally irradiated with 200 rads. A
total of 2 3 106 KG-1-LucNeo cells were injected via tail vein, and total body
leukemia burden was assessed by bioluminescence imaging (BLI) as previ-
ously described (Armstrong et al., 2003). Animals were imaged 5 and 7 days
after injection, and mice with established disease were divided into cohorts
that were treated with normal feed or feed impregnated with R788 at 5 g/kg
or 8 g/kg AIN-76A rodent diet. Serial imaging was used to assess disease
burden, and data were plotted as the mean ± standard error of the mean
(SEM) for each group. After 8 days on treatment, all mice were euthanized,
and tissue was collected. Spleen weights were expressed as mean ± SEM.
One way ANOVA analysis with Tukey post-test was used to determine the
significance of all pairwise comparisons.
Murine AML was induced by retroviral transduction of bone marrow with
MLL-AF9 as previously described (Stubbs et al., 2008). In brief, bone marrow
was harvested from a transgenic mouse with ubiquitous luciferase expression
(C57BL/6:UbC6-Luc) and transduced with a retrovirus encoding MLL-AF9
(MSCV-MLL-AF9-pgkNeo). Development of leukemia was determined by
BLI and clinical scoring. Thirty albino coisogenic mice (C57BL/6:TyrC/C, Jack-
son Labs) were sublethally irradiated with 300 rads, then injected with 106
mononuclear cells isolated from the spleen of a mouse with primary AML.
Mice underwent BLI weekly, and at 3 weeks postinjection, animals with docu-
mented disease (increasing bioluminescence) were divided into two cohorts of
mice with equal mean bioluminescence. The treatment group (n = 10) was
started on sdiet impregnated with R788 at 3 g/kg AIN-76A rodent diet. The
control group (n = 10) was kept on a normal diet. Mice underwent serial BLI
at the indicated days of treatment and were euthanized after the last imaging
time point, and tissue was collected. Total body bioluminescence was quanti-
tated with standardized regions of interest (Living Images, Caliper Life
Sciences) and are expressed as mean ± SEM. Statistical significance for BLI
data and spleen weights were calculated with Student’s t test.
For the primary human orthotopic model of AML, NOG mice were sublethally
irradiated with 200 rads and then injected by tail vein injection with 4 3 105
viable AML cells (Patient 11). Seventy days postinjection, mice developed
greater than 40% peripheral AML blasts, as measured by FACS analysis of
human specific CD45+ cells from peripheral blood. Mice were then divided
into two cohorts, with two animals per cohort. One group received 5g R788/
kg AIN-76 rodent diet, and the second, a placebo food. A NOG control mouse
without human AML was included. Six days posttreatment, tail vein blood was
sampled and peripheral AML blasts were again measured by FACS analysis of
human specific CD45+ cells. At day 7, animals were euthanized and tissue was
collected.
See Supplemental Experimental Procedures for the full details of experi-
mental methods.
Microarray Data
Previously published raw microarray data (Stegmaier et al., 2004) are available
at http://www.broad.mit.edu/cancer/pub/GE-HTS_leuk or http://www.ncbi.
nlm.nih.gov/geo.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, 13
figures, and 6 tables and can be found with this article online at http://www.
cell.com/cancer-cell/supplemental/S1535-6108(09)00291-8.ACKNOWLEDGMENTS
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